Activity ID
13666Expires
November 15, 2025Format Type
EnduringCME Credit
1Fee
$0CME Provider: Clinical Care Options, LLC
Description of CME Course
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Schizophrenia
ABMS Member Board Approvals by Type
ABMS Lifelong Learning CME Activity
Psychiatry and Neurology
Commercial Support?
YesNOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Educational Objectives
Assess evidence for efficacy and safety profiles of newer agents used in the treatment of schizophrenia
Differentiate characteristics of emerging treatments for schizophrenia including novel mechanisms of action, kinetics, efficacy, and AE profiles
Recognize the role of newer and emerging agents in addressing unmet needs in the current treatment of schizophrenia
Design a patient care plan that integrates novel agents into the current treatment of schizophrenia
Competencies
Medical Knowledge
CME Credit Type
AMA PRA Category 1 Credit
Practice Setting
Academic Medicine, Inpatient, Outpatient, Rural, Urban, VA/Military
